Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, and infectious disease.
About Codiak BioSciences
Founded
2015Estimated Revenue
$10M-$50MEmployees
51-250Funding / Mkt. Cap
$252MCategory
Industry
BiotechnologyLocation
City
CambridgeState
MassachusettsCountry
United StatesCodiak BioSciences
Find your buyer within Codiak BioSciences